NEKTAR THERAPEUTICS (NKTR)

US6402681083 - Common Stock

0.6125  0 (-0.5%)

Full estimates are only available for subscribed users, you can see which data is available below.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates.

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates


2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030
Revenue
152.9M
33.42%		101.907M
-33.35%		92.055M
-9.67%		86.117M
-6.45%
EBITDA
-365.7M
14.32%		-431.957M
-18.12%		-227.206M
47.40%		-215.444M
5.18%		N/AN/AN/AN/AN/A
EBIT
-379.9M
13.66%		-446.103M
-17.43%		-240.236M
46.15%		-224.025M
6.75%
Operating Margin
-248.46%-437.76%-260.97%-260.14%
EPS
-2.24
10.76%		-2.85
-27.23%		-1.97
30.88%		-1.40
29.09%		N/AN/AN/AN/A

All data in USD


Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates


Q3 / 23 Q4 / 23 Q1 / 24 Q2 / 24 Q3 / 24 Q4 / 24 Q1 / 25 Q2 / 25 Q3 / 25 Q4 / 25
EPS-0.20
35.32%
Revenue21.748K
-99.91%
EBITDA-29.56MN/AN/AN/AN/AN/AN/AN/AN/A
EBIT-34.602K
99.91%		N/AN/AN/AN/A

All data in USD


EPS and Revenue Surprises


Recent Earnings VS Estimates (USD)
Period Reported Estimate Difference Surprise Q2 2023 -0.27 -0.29 0.026.75% Q1 2023 -0.32 -0.26 -0.06-24.21% Q4 2022 -0.32 -0.46 0.1430.65% Q3 2022 -0.31 -0.46 0.1532.39% Q2 2022 -0.85 -0.95 0.1010.99% Q1 2022 -0.49 -0.69 0.2029.07% Q4 2021 -0.79 -0.83 0.044.31% Q3 2021 -0.70 -0.81 0.1114.04%
Recent Revenue VS Estimates (USD)
Period Reported Estimate Difference Surprise Q2 2023 20.499M 22.263K 20.477M91,976.42% Q1 2023 21.594M 20.235K 21.574M106,616.44% Q4 2022 22.023M 22.576K 22M97,448.88% Q3 2022 23.625M 23.061K 23.602M102,344.43% Q2 2022 21.585M 23.118M -1.533M-6.63% Q1 2022 24.822M 24.865M -43K-0.17% Q4 2021 25.009M 25.84M -831K-3.22% Q3 2021 24.921M 28.425M -3.504M-12.33%

EPS and Revenue Revisions


Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPS11.71% 16.17% 5.23% -43.74%
Revenue-99.9% -99.9% -2.38% 0.09%